The results of the trial showed there was still persistent blood flow in the oxymetazoline-only and saline-only groups. However, researchers found there was a higher rate of vascular shutdown with PDL and oxymetazoline (66.7%) than with PDL and saline (16.7%) — a 50% difference.
In addition, five minutes after oxymetazoline was applied, the venule diameter increased, while the arteriole and venule diameters decreased after 60 minutes of the application.
According to the researchers, “an increase in vessel diameter would increase the local volume of hemoglobin, which in turn would increase the volumetric heat generation resulting from PDL irradiation. The decrease in arteriole and venule diameter at 60 min may facilitate the ensuing photo‐induced coagulation effect.”
While the results of the preclinical trial show promise, clinical trials will still be required to establish the efficicacy and safety of the combination treatment. Limitations of the study include the small sample size of the trial, and the fact mice having different skin and vasculature dorsals than humans, according to the investigators.
With the possibility of the combination treatment moving to clinical trials, physicians could soon have another therapeutic option to offer patients with rosacea and other cutaneous vascular diseases.
1. Kelly A, Pai A, Lertsakdadet B, Choi B, Kelly KM. Microvascular Effects of Pulsed Dye Laser in Combination With Oxymetazoline. Lasers Surg Med. 2019;
2. Allergan Announces FDA Approval Of RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For The Topical Treatment Of Persistent Facial Erythema Associated With Rosacea In Adults. PR Newswire. https://www.prnewswire.com/news-releases/allergan-announces-fda-approval.... Published January 19 2017. Accessed December 4 2019.